View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Martijn Den Drijver
  • Martijn Den Drijver

Atenor SA: 1 director

A director at Atenor SA bought 251,231 shares at 2.800EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Stijn Demeester
  • Stijn Demeester

Umicore/Metals prices melt-up drives earnings upgrade/HOLD

We raise our 2025F-26F estimates for Umicore on the back of higher precious and platinum group metals prices, with our estimates for the battery materials business broadly unchanged. We raise our target price from €10 to €19 per share, driven by higher estimates and peer multiples, yet maintain our HOLD recommendation. Umicore shares have rallied +85% over the last year, largely driven by the melt-up in metals prices, although its earnings power in 2026F is likely moderated by elevated hedging l...

Umicore S.A.: 1 director

A director at Umicore S.A. bought 1,000 shares at 18.460EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Lynn Hautekeete
  • Wim Hoste
  • Wim Lewi
Wim Hoste
  • Wim Hoste

Umicore Walking on Sunshine - increasing target price to € 21

We upgrade our forecasts for the coming years with our 2030E adjusted EBITDA estimate upped by c. 8%. Loosening EU standards on CO2 emission regulation for cars & vans provide some additional support to the Catalysts business, whilst we have kept our forecasts for Battery Materials unchanged as these were already below the company's CMD targets and upside to our numbers will have to come from new supply arrangements/partnerships. The very strong metal price environment will most likely allow Umi...

Guy Sips ... (+4)
  • Guy Sips
  • Hilde Van Boxstael
  • Mathijs Geerts Danau
  • Wim Lewi
Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Mathijs Geerts Danau
  • Wim Lewi
Mathijs Geerts Danau
  • Mathijs Geerts Danau

Sequana Medical New DSR patent improves value of program

Sequana announces granting of a key additional methods and formulation patent for DSR. This patent increases durability and expands protection of Sequana's DSR IP, thereby improving its value. We note that the patent provides additional time for Sequana to secure dedicated financing to advance DSR toward the randomized controlled portion of the MOJAVE clinical study. We reiterate our BUY rating.

Wim Hoste
  • Wim Hoste

Umicore EU looks set to abandon combustion engine ban in 2035

Based on various press articles, it seems increasingly likely that the European Union is to abandon the earlier agreed ban on new combustion engine-based passenger cars by 2035, whilst new legislation would still require a significant reduction of tailpipe emissions. Any loosening of legislation would probably be good news for Umicore's Catalysts business, with European ICE Light duty Automotive Catalysts' revenue representing c. 28% of total ICE light duty Automotive Catalysts' revenue. We awai...

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi

Morning Notes : ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB...

: ACKB BB, AKZA NA, IBAB BB, ONTEX BB, SEQUA BB, XIOR BB, DEME BB, ARG FP, ZEAL DC

Mathijs Geerts Danau
  • Mathijs Geerts Danau

Sequana Medical Announces first US sale of the alfapump

Sequana reported the first US commercial alfapump implant at Mount Sinai Hospital in New York. This important milestone shows the demand for the alfapump in the US. We adjust our TP from € 2.8 to € 2.7 to reflect the new share count and reiterate our BUY rating.

Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Thibault Leneeuw
  • Wim Lewi
Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi
Guy Sips ... (+4)
  • Guy Sips
  • Jacob Mekhael
  • Livio Luyten
  • Wim Hoste
Guy Sips ... (+3)
  • Guy Sips
  • Jacob Mekhael
  • Wim Hoste
Wim Hoste
  • Wim Hoste

Umicore FIRST LOOK: Silicon-anodes JV with HS Hyosung Advance Material...

After more than a decade of R&D efforts on developing silicon carbon composite anode materials for EV batteries, Umicore now believes its technology is ready for industrialization & commercialization and has announced its intention to create a JV with HS Hyosung Advanced Materials. Umicore will retain a minority stake in the JV, which will allow the group to limit expenditure for the roll-out of its anode technology. This approach is very much in sync with the approach taken for the cathode acti...

Guy Sips ... (+6)
  • Guy Sips
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Hoste

Morning Notes : ABI BB, ASML NA, BAR BB, OPTI BB, HEIA NA, IVA FP, PRO...

: ABI BB, ASML NA, BAR BB, OPTI BB, HEIA NA, IVA FP, PROX BB, SEQUA BB, MRUS US

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch